NCT06181032View on ClinicalTrials.gov

A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 23, 2023

Primary Completion Date

February 23, 2029

Study Completion Date

February 23, 2029

Conditions
Biliary Tract Malignancies
Interventions
DRUG

Adebrelimab

Adebrelimab: 1200mg or 20mg/kg, iv, D1, Q3W;

DRUG

Apatinib

Apatinib: 250 mg, po, QD, Q3W;

DRUG

Gemcitabine

Gemcitabine: 1000 mg/m2, iv, 30min, D1, D8, Q3W;

DRUG

Cisplatin

Cisplatin: 25 mg/m2, iv, 30min, D1, D8, Q3W; Injection sequence: adebelizumab → gemcitabine → cisplatin (sequential interval of at least 30 min), 3 cycles of neoadjuvant therapy.

Trial Locations (1)

350000

RECRUITING

The First Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

First Affiliated Hospital of Fujian Medical University

OTHER